Pharmacotherapy of essential thrombocythaemia: Economic considerations

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 9, 2003, Pages 1499-1505

  Griesshammer, Martin ^a   Langer, Christian ^a  

^a Department of Medicine III ^*  (Germany)

Author keywords

Anagrelide; Aspirin; Economic considerations; Essential thrombocythaemia; Hydroxyurea; Interferon ; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; BUSULFAN; CYTOTOXIC AGENT; HYDROXYUREA; INTERFERON; PIPOBROMAN;

ABDOMINAL PAIN; ACUTE LEUKEMIA; AGE DISTRIBUTION; ALOPECIA; ANEMIA; BLEEDING; CLINICAL OBSERVATION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIARRHEA; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG PREFERENCE; DRUG SAFETY; FATIGUE; FLU LIKE SYNDROME; FLUID RETENTION; HEADACHE; HEALTH ECONOMICS; HEART PALPITATION; HIGH RISK PATIENT; HUMAN; HYPERPIGMENTATION; LEG ULCER; LEUKOPENIA; MEGALOBLASTIC ANEMIA; MYALGIA; NAIL DISEASE; NAUSEA; NEUTROPENIA; RASH; REVIEW; RISK ASSESSMENT; SECOND CANCER; SKIN CANCER; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOEMBOLISM; TREATMENT INDICATION; VERTIGO; WEIGHT REDUCTION;

AGE FACTORS; ANTINEOPLASTIC AGENTS; ASPIRIN; CLINICAL TRIALS, PHASE II; COST-BENEFIT ANALYSIS; HUMANS; HYDROXYUREA; INTERFERON-ALPHA; PIPOBROMAN; QUINAZOLINES; RISK FACTORS; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 0141740256     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.9.1499     Document Type: Review

References (44)

1. RIDELL B, CARNESKOG J, WEDEL H et al.: Incidence of chronic myeloproliferative disorders in the city of Goteborg, Sweden 1983-1992. Eur. J. Hematol. (2000) 65:267-271.
2. ROZMAN C, GIRALT M, FELIU E et al.: Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer (1991) 67:2658-2663.
3. TEFFERI A, MURPHY S: Current option in essential thrombocythemia: pathogenesis, diagnosis and management. Blood reviews (2001) 15:121-131.
4. TEFFERI A, SOLBERG LA, SILVERSTEIN MN: A clinical update in polycydiemia vera and essential thrombocythemia. Am. J. Med. (2000) 109:141-149.
5. RUGGERI M, FINAZZI G, TOSETTO A et al.: No treatment for low-risk thrombocythaemia: results from a prospective study. Br. J. Haematol. (1998) 103:772-777.
6. MICHIELS JJ, VAN GENDEREN PJJ, LINDEMANS J, VAN VLIET HHDM: Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia. Leuk. Lymphoma (1996) 22(Suppl. 1):47-56.
7. PEARSON TC: The risk of thrombosis in essential thrombocythemia and polycythemia vera. Semin. Oncol. (2002) 29:16-21.
8. GENDEREN VAN PJJ, BUDDE U, MICHIELS JJ et al.: The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count. Br. J. Haematol. (1996) 93:962-965.
9. BESSES C, CERVANTES F, PEREIRA A et al.: Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia (1999) 13:150-154.
10. CORTELAZZO S, VIERO P, FINAZZI G et al.: Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J. Clin. Oncol. (1990) 8:556-562.
11. COLOMBI M, RADAELLI F, ZOCCHI L, MAIOLO AT: Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer (1991) 67:2926-2930.
12. JANTUNEN R, JUVONEN E, IKKALA E et al.: The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia. Ann. Hematol. (2001) 80:74-78.
13. BELLUCCI S, JANVIER M, TOBELEM G et al.: Essential thrombocythemias: clinical evolutionary and biological data. Cancer (1986) 58:2440-2447.
14. FENAUX P, SIMON M, CAULIER MT et al.: Clinical course of essential thrombocythemia in 147 cases. Cancer (1990) 66:549-556.
15. LAHUERTA-PALACIOS JJL, BORNSTEIN R, FERNANDEZ-DEBORA FJ et al.: Controlled and uncontrolled thrombocytosis. Its clinical role in thrombocythemia. Cancer (1988) 61:1207-1212.
16. PEARSON TC, BAREFORD D, CRAIG J et al.: The management of low-risk and intermediate-risk patients with primary thrombocythaemia. Br. J. Haematol. (1999) 106:833.
17. BARBUI T, FINAZZI G: Clinical parameters for determing when and when not to treat essential thrombocythemia. Semin. Hematol. (1999) 36(Suppl. 2):14-18.
18. GRIESSHAMMER M, BERGMANN L, HAFNER M et al.: Treatment and clinical course of essential thrombocythemia (ET): preliminary results of a prospective multicenter trial. Blood (1998) 92(Suppl. 1):423a (Abstract 1750).
19. CORTELAZZO S, FINAZZI G, RUGGERI M et al.: Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N. Engl. J. Med. (1995) 332:1132-1136.
20. WEINFELD A, SWOLIN B, WESTIN J: Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur. J. Haematol. (1994) 52:134-139.
21. NAND S, STOCK W, GODWIN J, FISHER SG: Leukemogenic risk of hydroxyurea therapy in polycythaemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Am. J. Hematol. (1996) 52:42-46.
22. STERKERS Y, PREUDHOMME C, LAI JL et al.: Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood (1998) 91:616-622.
23. MURPHY S, PETERSON P, ILAND H, LASZLO J: Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival and leukemic transition by treatment. Semin. Hematol. (1997) 34:29-39.
24. FINAZZI G, RUGGERI M, RODEGHIERO F, BARBUI T: Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clincial trial. Br. J. Haematol. (2000) 110:577-583.
25. HANFT VN, FRUCHTMAN SR, PICKENS CV et al.: Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood (2000) 95:3589-3593.
26. FINAZZI G, RUGGERI M, RODEGHIERO F, BARBUI T: Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. Blood (2003) 101:3749.
27. PASSAMONTI F, MALABARBA L, ORLANDI E et al.: Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. Br. J. Haematol. (2002) 116:855-861.
28. KILADJIAN JJ, GARDIN C, RENOUX M et al.: Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. Hematol. J. (2003) 4:198-207.
29. LENGFELDER E, GRIESSHAMMER M, HEHLMANN R: Interferon-alpha in the treatment of essential thrombocythemia. Leuk. Lymhoma (1996) 22(Suppl. 1):135-142.
30. ELLIOT MA, TEFFERI A: Interferon-α therapy in polycythaemia vera and essential thrombocythemia. Sem. Thromb. Hemost. (1997) 23:463-472.
31. GILBERT HS: Long term treatment of myeloproliferative disease with Interferon-alpha-2b: feasability and efficacy. Cancer (1998) 83:1205-1213.
32. BENTLEY M, TAYLOR K, GRIGG A et al.: Long-term interferon-alpha-2a does not induce sustained hematologic remission in younger patients with essential thrombocythemia. Leuk. Lymphoma (1999) 36:123-128.
33. ALVARADO Y, CORTES J, VERSTOVSEK S et al.: Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother. Pharmacol. (2003) 51:81-86.
34. TOMER A: Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. Bload (2002) 99:1602-1609.
35. STOREN EC, TEFFERI A: Long-term use of anagrelide in young patients with essential thrombocythemia. Blood (2001) 97:863-866.
36. GRIESSHAMMER M, BANGERTER M, VAN VLIET HH, MICHIELS JJ: Aspirin in essential thrombocythemia: status quo and quo vadis. Semin. Thromb. Hemost. (1997) 23:371-377.
37. ROCCA B, CIABATTONI G, TARTAGLIONE R et al.: Increased thromboxane biosynthesis in essential thrombocythemia. Thromb. Haemost. (1995) 74:1225-1230.
38. GENDEREN VAN PJJ, MULDER PGH, WALEBOER M et al.: Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. Br. J. Haematol. (1997) 97:179-184.
39. GENDEREN VAN PJJ, PRINS FJ, MICHIELS JJ et al.: Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: a rationale for the use of low-dose aspirin as an antithrombotic agent. Br. J. Haematol. (1999) 104:438-441.
40. MAGEN-NATIV H, STARK P, KADOSH S et al.: Hemostatic complications and role of aspirin in myeloproliferative disorders: result of long term follow-up of 394 patients. Haematol. J. (2000) 1(Suppl.1):75 (Abstract).
41. THIELE J, KVASNICKA HM: Chronic myeloproliferative disorders. The new WHO classification. Pathologe (2001) 22:429-443.
42. GOLUB R, ADAMS J, DAVE S, BENNETT CL: Cost-effectiveness considerations in the treatment of essential thrombocythemia. Semin. Oncol. (2000) 29:28-32.
43. BENNETT CL, WEINBERG PO, GOLUB RM: Cost-effectiveness model of a phase II clinical trial of a new pharmaceutical for essential thrombocythemia: is it helpful to policy makers? Semin. Hematol. (1999) 36:26-29.
44. Anagrelide project #29Z: integrated summary of efficacy (final report), Roberts Pharmaceuticals, Eatontown, NJ, USA (1995).